Pacira Q2 FY26 returns to GAAP profit of USD 4.7 million; revenue rises 6% to USD 192.4 million

• Pacira posted Q2 GAAP net income of USD 4.7 million, or USD 0.12 per share, swinging from a year-earlier loss.
• Revenue rose 6% year over year to USD 192.4 million, led by EXPAREL at USD 147.8 million, up 3%.
• Adjusted EBITDA fell 10% to USD 48.7 million; non-GAAP net income declined 18.02% to USD 29.5 million.
• Closed iovera° divestiture to Zimmer Biomet for up to USD 140 million, including USD 70 million upfront; received USD 73.6 million cash.
• Cut 2026 revenue outlook to USD 735 million-USD 760 million; reiterated EXPAREL sales view of USD 600 million-USD 620 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608041601PRIMZONEFULLFEED9803534) on August 04, 2026, and is solely responsible for the information contained therein.